

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Filgotinib for treating moderately to severely active ulcerative colitis

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| Scoping identified that the mode of administration (oral) is a benefit for those with disabilities in terms of reducing the need to travel to hospital, potentially improving adherence. This may also be a factor in cultures where it may be harder to speak openly about the condition or for those living in remote communities.

The committee discussed the mode of administration of filgotinib. It did not consider any issues raised were relevant since filgotinib is recommended for all people with moderate to severe active ulcerative colitis including those with disabilities. |
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| Yes, it was raised that for certain religious groups the impact of active disease and the effects of surgery may interfere with religious practices and cause distress. The committee did not consider any issues raised were relevant since filgotinib is recommended and this would apply to all people with moderate to severe active ulcerative colitis including those in religious groups. |

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes. Equality issues have described in section 3.20 of the FAD.

Approved by Associate Director (name): Henry Edwards

Date: 04/04/2022